OrthoPediatrics (NASDAQ:KIDS) Issues Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• OrthoPediatrics reported earnings of ($0.11) per share, surpassing the expected ($0.17) EPS by $0.06.
• Shares fell by 1.7% to $20.19, with a market capitalization of $490.42 million and trading volume above its average.
• Despite recent mixed analyst ratings, the company has a consensus rating of "Moderate Buy" with an average price target of $35.83.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06, Zacks reports. OrthoPediatrics had a negative net margin of 19.15% and a negative return on equity of 7.03%. OrthoPediatrics updated its FY 2025 guidance to EPS.

OrthoPediatrics Stock Down 1.7%

Shares of KIDS stock traded down $0.34 during trading hours on Tuesday, hitting $20.19. 288,668 shares of the company were exchanged, compared to its average volume of 200,275. The company has a market capitalization of $490.42 million, a PE ratio of -11.54 and a beta of 1.12. OrthoPediatrics has a 52 week low of $19.51 and a 52 week high of $33.14. The business has a 50 day moving average of $21.50 and a two-hundred day moving average of $22.80. The company has a current ratio of 6.19, a quick ratio of 2.99 and a debt-to-equity ratio of 0.21.

Institutional Trading of OrthoPediatrics

A number of hedge funds have recently modified their holdings of the stock. Millennium Management LLC raised its stake in OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company's stock worth $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock worth $4,937,000 after purchasing an additional 106,041 shares in the last quarter. Jane Street Group LLC acquired a new stake in OrthoPediatrics in the 1st quarter worth about $389,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after purchasing an additional 645 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a research report on Thursday, May 8th. BTIG Research restated a "buy" rating on shares of OrthoPediatrics in a report on Monday, July 14th. Lake Street Capital assumed coverage on shares of OrthoPediatrics in a report on Monday, April 7th. They issued a "buy" rating and a $37.00 target price on the stock. Wall Street Zen downgraded shares of OrthoPediatrics from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Finally, Truist Financial lowered their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, OrthoPediatrics has a consensus rating of "Moderate Buy" and an average price target of $35.83.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.